Get the Stockscreener App
1.185
4.37%
-0.075
After Hours:
1.22
0.035
+2.95%
Prime Medicine Inc stock is traded at $1.185, with a volume of 1.23M.
It is down -4.37% in the last 24 hours and down -30.35% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$1.26
Open:
$1.24
24h Volume:
1.23M
Relative Volume:
0.69
Market Cap:
$154.92M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-0.5461
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-6.59%
1M Performance:
-30.35%
6M Performance:
-63.37%
1Y Performance:
-81.46%
1-Day Range:
$1.18
$1.245
1-Week Range:
$1.18
$1.35
52-Week Range:
$1.11
$8.1442
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.18 | 161.49M | 0 | -217.44M | -205.20M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits - Genetic Engineering and Biotechnology News
Prime Medicine downgraded to Neutral from Overweight at JPMorgan - TipRanks
Prime Medicine to deprioritize CGD programs, reduce headcount by 25% - TipRanks
6 Analysts Assess Prime Medicine: What You Need To Know - Benzinga
CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff - The Boston Globe
Jefferies cuts Prime Medicine stock target to $9, maintains Buy By Investing.com - Investing.com Canada
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating - marketscreener.com
David Liu gene-editing startup cuts staff, names new CEO - The Business Journals
PRME: Chardan Capital Adjusts Price Target for Prime Medicine | - GuruFocus
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Prime Medicine price target lowered to $12 from $16 at Chardan - TipRanks
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish By Stocktwits - Investing.com India
Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating - marketscreener.com
Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot - BioPharma Dive
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
Prime Medicine CEO Keith Gottesdiener to step down, Allan Reine to succeed - TipRanks
Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25%Stock Plunges - Nasdaq
Prime Medicine (PRME) Shares Plunge Amid Leadership Change and Strategic Shift - GuruFocus
Prime Medicine stock plummets amid restructuring and leadership changes By Investing.com - Investing.com South Africa
Prime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term Volatility - TipRanks
Prime Medicine (PRME) Reports Promising Results from PM359 Clini - GuruFocus
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):